Systems and methods are provided herein for treating a patient in cardiogenic shock. An intravascular heart pump system is inserted into vasculature of the patient. The heart pump system has a cannula, pump outlet, pump inlet, and rotor. The heart pump system is positioned within the patient such that the cannula extends across the patient's aortic valve, the pump inlet is located within the patient's left ventricle, and the pump outlet is located within the patient's aorta. Data related to time-varying parameters of the heart pump system is acquired from the heart pump system. A plurality of features are extracted from the data. A probability of survival of the patient is determined based on the plurality of features and using a prediction model. The heart pump system is operated to treat the patient.

Macroencapsulation devices and their methods of use are disclosed. In one embodiment, a macroencapsulation device may include a first outer membrane, a second outer membrane, and at least one semipermeable membrane disposed there between to form at least a primary compartment configured to house a first population of cells and a secondary compartment in fluid communication with the primary compartment through the first semipermeable membrane. In some embodiments, the flow of material into and out of the compartments of the macroencapsulation device and/or the application of an appropriate pressure differential between the compartments may be used to control the flow of filtrates, ancillary agents, and other materials between the compartments of the device when positioned in vivo.

An apparatus for draining lymph into vein includes a drainage device. The drainage device includes a chamber, an osmosis membrane, a first catheter, a second sensing element, and a pump. The chamber includes a chamber wall, wherein a chamber space is formed by the chamber wall, and a first opening is formed on the chamber wall. The osmosis membrane disposed on the first opening. One end of the first catheter connects to the chamber space, and the other end of the first catheter connects with a vein. The second sensing element receives a radio wave emitted by a first sensing element of a power supply device to send an electrical signal. The pump is disposed in the chamber and connecting to the second sensing element, wherein a negative pressure in the chamber space is generated by the pump to drain lymph into the vein via the first catheter.

The present invention relates to methods for encapsulating pancreatic progenitors in a biocompatible semi-permeable encapsulating device. The present invention also relates to production of human insulin in a mammal in response to glucose stimulation.

The invention relates to a metallic, nanoporous canister used to encapsulate cellular and/or biotherapeutic agents. The device is biocompatible and functions to wholly isolate a therapeutically active agent and/or cells therein. Their implantation, and survival in vivo, permits the local or systemic diffusion of their encapsulated cellular and/or biomolecular and therapeutics factors with the potential to promote repair of damaged or degenerated tissues in mammalian hosts, primarily humans.

The present technology includes systems and methods for invasively adjusting implantable devices for selectively controlling fluid flow between a first body region and a second body region of a patient. For example, in many of the embodiments described herein, a catheter can be used to mechanically and/or electrically engage an implanted medical device. Once the catheter engages the medical device, the catheter can (i) increase a dimension associated with the medical device, such as through mechanical expansion forces, and/or (ii) decrease a dimension associated with the medical device, such as by heating a shape memory component of the medical device above a phase transition temperature.

An arteriovenous graft system is described. The arteriovenous graft system includes an arteriovenous graft that is suited for use during hemodialysis. In order to minimize or prevent arterial steal, at least one valve device is positioned at the arterial end of the arteriovenous graft. In one embodiment, for instance, the arteriovenous graft systems includes a first valve device positioned at the arterial end and a second valve device positioned at the venous end. In one embodiment, the valve devices may include an inflatable balloon that, when inflated, constricts and closes off the arteriovenous graft. If desired, a single actuator can be used to open and close both valve devices.

An apparatus for loading an endovascular shunt into a delivery catheter includes a base, a boss rod connected to, and extending longitudinally across, the base, and a plurality of guide bosses slidably coupled to the boss rod. The guide bosses include a delivery catheter guide boss coupled to the delivery catheter, a malecot holding tube guide boss, wherein a malecot holding tube is connected to a first lateral side of the malecot guide boss extending towards the delivery catheter guide boss, a claw assembly guide boss, where a claw assembly is attached to a first lateral side of the claw guide boss extending towards the malecot holding tube guide boss, and a chase pin guide boss, wherein a chase pin is connected to a first lateral side of the chase pin guide boss extending towards the claw assembly guide boss.

Systems and methods can be employed for trans-tympanic membrane access to the middle ear for delivery of a therapeutic agent, for example, to the round window niche adjacent to the cochlea under direct visualization. The systems and methods can also be used to improve accessibility and visualization for various otological surgical procedures, such as, but not limited to, cholesteatoma removal, tympanic membrane repair and ossicular chain repair.

An intrathecal drug delivery system including an intrathecal drug delivery device configured to deliver a fluid containing one or more pharmaceutical agents intrathecally to CSF within a spinal canal of a patient, a deep brain catheter having an elongated body extending from distal end is configured implanted within a deep brain structure of a patient and a proximal end positioned within the subarachnoid space directly adjacent to the brain to provide a passageway via an inner lumen between subarachnoid space and the deep structure. The drug delivery system configured to transport the pharmaceutical agent using diffusion and pulsatile flow of the CSF through the deep brain catheter from the subarachnoid space to the deep brain structure.